These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3624101)

  • 41. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigational new drug applications and new drug applications--FDA. Final rule.
    Fed Regist; 1998 Feb; 63(28):6854-62. PubMed ID: 10177736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expanded access to investigational drugs for treatment use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An update of antidote availability in veterinary medicine.
    Post LO; Keller WC
    Vet Hum Toxicol; 1999 Aug; 41(4):258-61. PubMed ID: 10434385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Oct; 68(201):59714-5. PubMed ID: 14567392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Research activities in the Bureau of Veterinary Medicine.
    Norcross MA
    J Am Vet Med Assoc; 1982 Jan; 180(1):32. PubMed ID: 7199037
    [No Abstract]   [Full Text] [Related]  

  • 47. Regulatory issues for evaluation of therapies to prevent or arrest disease progression.
    Hyman FN; Welch ME; Cheever JR
    Ann Periodontol; 1997 Mar; 2(1):166-79. PubMed ID: 9151552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Requirements for Foreign and Domestic Establishment Registration and Listing for Human Drugs, Including Drugs That Are Regulated Under a Biologics License Application, and Animal Drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Aug; 81(169):60169-224. PubMed ID: 27580511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delegations of authority and organization; Office of the Commissioner--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758. PubMed ID: 10115698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The FDA's new procedures for the use of investigational drugs in treatment.
    Young FE; Norris JA; Levitt JA; Nightingale SL
    JAMA; 1988 Apr; 259(15):2267-70. PubMed ID: 3280842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. THE IMPACT OF RECENT REGULATIONS OF THE FEDERAL FOOD AND DRUG ADMINISTRATION ON CLINICAL INVESTIGATION OF NEW DRUGS IN DENTISTRY: THE VIEW OF THE CLINICAL INVESTIGATOR.
    KUTSCHER AH; ZEGARELLI EV
    J Oral Ther Pharmacol; 1964 Jul; 1():79-84. PubMed ID: 14204418
    [No Abstract]   [Full Text] [Related]  

  • 53. The 21 CFR (Code of Federal Regulations) online database: Food and Drug Administration regulations full-text.
    Bobka MS
    Med Ref Serv Q; 1993; 12(1):7-15. PubMed ID: 10126251
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Promoting Patient Interests in Implementing the Federal Right to Try Act.
    Lynch HF; Zettler PJ; Sarpatwari A
    JAMA; 2018 Sep; 320(9):869-870. PubMed ID: 30105394
    [No Abstract]   [Full Text] [Related]  

  • 55. Regulation of animal care and research. The final order on Good Laboratory Practices.
    Lepore PD; Crawford LM
    J Anim Sci; 1980 Aug; 51(2):474-8. PubMed ID: 7440439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reporting of deaths during pre-approval clinical trials for advanced HIV-infected populations.
    Johann-Liang R; James AN; Behr VL; Struble K; Birnkrant DB
    Drug Saf; 2005; 28(7):559-64. PubMed ID: 15963004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hormonal and antimicrobial therapy in theriogenology practice: currently approved drugs in the USA and possible future directions.
    Modric T; Momcilovic D; Gwin WE; Peter AT
    Theriogenology; 2011 Aug; 76(3):393-408. PubMed ID: 21601267
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New drugs for human use; clarification of requirements for patent holder notification--FDA. Proposed rule.
    Fed Regist; 1998 Mar; 63(44):11174-7. PubMed ID: 10177511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.